Brind.

Morgan Stanley assumed coverage of Axsome Therapeutics with an Overweight rating on July 6, 2025.

1 report, 0 independent Updated Jul 6

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Axsome Therapeutics Morgan Stanley

Keep exploring

The entities involved

Axsome Therapeutics
American biopharmaceutical company

Nothing else this week.
Morgan Stanley
U.S. investment bank
- Financial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Mon 17:33
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24

Related events

Morgan Stanley and Manufacturers Life Insurance Company purchased a new position and reiterated an overweight rating for Monopar Therapeutics.Aug 18

Coverage

Newest first; wire copies grouped

Jul 6Unknown outlet